Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Inclusion Criteria

• •Age 18 or older
• •Diagnosis of T-LGLL defined as: CD3+CD8+ cell population \> 650/mm\^3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis). This also includes patients with rare T-LGLL variants include CD4+ T-LGLL, and gamma/delta T-LGLL which can be CD4- and CD8, though patients still must have an LGL cell population \>500 cells/mm3 and the presence of a clonal T-cell receptor within 1 month of diagnosis or relapse. Note: patients with myelodysplastic syndrome (MDS)-like T-LGLL may be included with principal investigator (PI) approval even if CD3+CD8+ cell population is \< 650/mm\^3, though +TCR is required. Natural-killer (NK) large granular lymphocytic leukemia (LGL) is also permitted, provided there is a clonal NK-cell population noted with \> 500 cells/mm\^3
• •Failed at least one line of frontline therapy; off treatment for at least 14 days or 5 half-lives, whichever is longer
• •Require Treatment for T-LGLL (One or more required)
• •* Symptomatic anemia with hemoglobin \< 10 g/dL
• •* Transfusion-dependent anemia
• •* Neutropenia with absolute neutrophil count (ANC) \< 500/mm\^3
• •* Neutropenia with ANC \< 1500/mm\^3 with recurrent infections
• •Platelet count \>= 50 x 10\^9/L
• •Serum creatinine =\< 2 x the upper limit of normal (ULN)
• •Total bilirubin =\< 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin \> 1.5 x ULN permitted)
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 1.5 x ULN
• •Eastern cooperative oncology group (ECOG) performance status =\< 2
• •Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study
• •Able to sign informed consent